Aleyamma Jacob, MD
Internal Medicine · Westbury, NYNPI 1932153996
Payments from drug & device makers
Across 642 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- AstraZeneca$2K
- Novo Nordisk$2K
- AbbVie$1K
- Lilly USA, LLC$1K
- Amgen$895
- plus $4K from 30 others
What the payments were for
- Food & beverage$13,30199%
- Education$1631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 95 | $2,448 |
| AstraZeneca | 111 | $2,220 |
| Novo Nordisk | 89 | $1,603 |
| AbbVie(2 entities) | 54 | $1,124 |
| Lilly USA, LLC | 51 | $1,079 |
| Amgen | 45 | $895 |
| Merck | 34 | $628 |
| Alkermes, Inc. | 23 | $590 |
| Orexo US, Inc. | 26 | $397 |
| Pfizer | 13 | $277 |
| Indivior Inc. | 12 | $242 |
| Mannkind Corporation | 11 | $231 |
| Teva Pharmaceuticals USA, Inc. | 6 | $216 |
| Amarin Pharma, Inc. | 10 | $207 |
| Astellas Pharma US Inc | 6 | $202 |
| Ardelyx, Inc. | 6 | $141 |
| Johnson & Johnson | 6 | $107 |
| Exact Sciences | 4 | $95 |
| Novartis | 5 | $90 |
| Abbott | 4 | $80 |
| GSK | 5 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
| Esperion Therapeutics, Inc. | 4 | $75 |
| Dexcom, Inc. | 3 | $55 |
| Braeburn Inc. | 2 | $48 |
| Lundbeck LLC | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Corium, LLC | 1 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
| BETA Bionics, Inc. | 1 | $21 |
| Neos Therapeutics, LP | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Seqirus USA Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,464 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 53 | $69,834 |
| JardianceEmpagliflozin | 42 | $67,774 |
| OzempicSemaglutide | 36 | $64,558 |
| EliquisApixaban | 32 | $37,584 |
| JanuviaSitagliptin Phosphate | 21 | $31,012 |
| TradjentaLinagliptin | 18 | $26,076 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $21,367 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $13,394 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $11,351 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 97 | $8,601 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $7,095 |
| Novolog FlexpenInsulin Aspart | 21 | $6,709 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 84 | $2,812 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 17 | $2,187 |
| Rosuvastatin Calcium | 268 | $1,794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $2,448 | $93,85060 claims |
| AstraZenecaFarxiga | $2,220 | $69,83453 claims |
| Novo NordiskOzempic | $1,603 | $64,55836 claims |
| PfizerEliquis | $277 | $37,58432 claims |
| MerckJanuvia | $628 | $31,01221 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $79 | $24,74426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Westbury
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.